Profitelligence Profitelligence · Filing Ledger Open ROIV research →

Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-06-20

Pulik Richard Files Roivant Sciences Ltd (ROIV) Form 4 - June 20, 2026

Pulik Richard sold 2.1K ROIV shares worth $66.9K in this Form 4 filing, reported to the SEC on 2026-06-20.

Insider
Pulik Richard
Issuer
Roivant Sciences Ltd ROIV · NASDAQ
Filed
Period
2026-06-20
Accession
0001635088-26-000069

Transactions (1)

Insider Date Type Shares Price Value Own
Pulik Richard 2026-06-20 Sell 2.1K $31.43 $66.9K Direct
Net change−2.1K−$66.9K

About Roivant Sciences Ltd

Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.

Exchange NASDAQ Industry Biotechnology Company website ↗

Track ROIV insider activity

Get alerted when Roivant Sciences Ltd executives buy or sell their shares.

Set up free alerts